17.38
0.48 (2.84%)
| Previous Close | 16.90 |
| Open | 16.76 |
| Volume | 1,080,730 |
| Avg. Volume (3M) | 2,118,447 |
| Market Cap | 1,460,232,320 |
| Price / Book | 5.02 |
| 52 Weeks Range | |
| Earnings Date | 5 Mar 2026 |
| Diluted EPS (TTM) | -0.750 |
| Total Debt/Equity (MRQ) | 9.89% |
| Current Ratio (MRQ) | 7.27 |
| Operating Cash Flow (TTM) | -91.95 M |
| Levered Free Cash Flow (TTM) | -96.27 M |
| Return on Assets (TTM) | -25.84% |
| Return on Equity (TTM) | -37.06% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Mind Medicine (MindMed) Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 3.5 |
| Insider Activity | NA |
| Price Volatility | -5.0 |
| Technical Moving Averages | -1.0 |
| Technical Oscillators | 0.5 |
| Average | -0.50 |
|
Mind Medicine Inc. is a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. It is developing a pipeline of product candidates targeting neurotransmitter pathways that play key roles in brain health disorders. This includes explicitly pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM120 and MM402, as its key product candidates. The MM120 is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that is being developed to treat generalized anxiety disorder and clinical depressive disorder, and the MM402 is a proprietary form of the R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA), being developed to treat autism spectrum disorder (ASD). |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 0.85% |
| % Held by Institutions | 55.15% |
| 52 Weeks Range | ||
| Median | 61.00 (250.98%) | |
| Total | 1 Buy | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Jones Trading | 23 Dec 2025 | 61.00 (250.98%) | Buy | 14.02 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |